{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:24:26Z","timestamp":1791944666291,"version":"4.3.4"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dual antiplatelet therapy with acetylsalicylic acid (ASA) and an oral P2Y12 inhibitor is the standard of care to prevent thrombotic complications in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). However, the oral administration of P2Y12 inhibitors bears significant limitations in acute and high-risk PCIs, particularly in ST-elevation myocardial infarction (STEMI) patients, especially those presenting with cardiogenic shock (CS) and cardiac arrest (CA). In these cases, factors such as active vomiting, altered physiology, sedatives, mechanical ventilation, and therapeutic hypothermia can impair drug absorption, reducing the intended antiplatelet effect and increasing ischaemic risk. In these cases, intravenous antiplatelet strategies with ASA and cangrelor could guarantee adequate periprocedural platelet inhibition. Here, we discuss the role of cangrelor in acute and high-risk PCI settings. The pharmacokinetic and pharmacodynamic attributes of cangrelor are discussed first, underscoring the distinctive features that make cangrelor an attractive antiplatelet agent in acute PCI settings. The second part of the review summarizes the evidence from real-world studies that illustrate how cangrelor has been adopted in contemporary practice. Finally, we provide a practical guide to cangrelor use, including recommendations for transitioning from cangrelor to oral P2Y12 inhibitors after PCI.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvaf042","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:51:49Z","timestamp":1749023509000},"page":"540-551","source":"Crossref","is-referenced-by-count":6,"title":["The role of cangrelor in acute and high-risk PCI settings"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-283X","authenticated-orcid":false,"given":"Uwe","family":"Zeymer","sequence":"first","affiliation":[{"name":"Institut f\u00fcr Herzinfarktforschung Ludwigshafen , Bremserstrasse 79, Ludwigshafen 67063 ,","place":["Germany"]},{"name":"Faculty of Medicine, University Heart Center Freiburg-Bad Krozingen, University of Freiburg , S\u00fcdring 15, Bad Krozingen 79189 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital T\u00fcbingen , T\u00fcbingen 72076 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-1956","authenticated-orcid":false,"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University Heart Center Freiburg-Bad Krozingen, University of Freiburg , S\u00fcdring 15, Bad Krozingen 79189 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wilhelminen Hospital , Vienna 1090 ,","place":["Austria"]},{"name":"Sigmund Freud University , Vienna 1020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025092123022045700_pvaf042-B1","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"2025092123022045700_pvaf042-B2","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025092123022045700_pvaf042-B3","first-page":"221","article-title":"Antiplatelet therapy in percutaneous coronary intervention","volume":"5","author":"Fanaroff","year":"2016","journal-title":"Interv Cardiol Clin"},{"key":"2025092123022045700_pvaf042-B4","doi-asserted-by":"crossref","first-page":"e2134322","DOI":"10.1001\/jamanetworkopen.2021.34322","article-title":"Assessment of pretreatment with oral P2Y12 inhibitors and cardiovascular and bleeding outcomes in patients with non-ST elevation acute coronary syndromes: a systematic review and meta-analysis","volume":"4","author":"Dawson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025092123022045700_pvaf042-B5","first-page":"e344","article-title":"2014 AHA\/ACC Guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"2025092123022045700_pvaf042-B6","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS)Developed with the special contribution o","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"2025092123022045700_pvaf042-B7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2025092123022045700_pvaf042-B8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with Prasugrel in non\u2013ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"2025092123022045700_pvaf042-B9","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of oral P2Y12 inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome","volume":"76","author":"Tarantini","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092123022045700_pvaf042-B10","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N Engl J Med"},{"key":"2025092123022045700_pvaf042-B11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.thromres.2008.01.021","article-title":"Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction","volume":"122","author":"Heestermans","year":"2008","journal-title":"Thromb Res"},{"key":"2025092123022045700_pvaf042-B12","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1002\/ehf2.13643","article-title":"Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature","volume":"8","author":"Radu","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025092123022045700_pvaf042-B13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijcard.2016.04.077","article-title":"Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors","volume":"215","author":"Kubica","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025092123022045700_pvaf042-B14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2013.10.068","article-title":"Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Hobl","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025092123022045700_pvaf042-B15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and actioninpatients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur Heart J"},{"key":"2025092123022045700_pvaf042-B16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.117.031678","article-title":"Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (platelet aggregation with ticagrelor inhibition and fentanyl)","volume":"137","author":"McEvoy","year":"2018","journal-title":"Circulation"},{"key":"2025092123022045700_pvaf042-B17","first-page":"1269","article-title":"Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: the CANGRELOR-OHCA Study","volume":"18","author":"Kordis","year":"2023","journal-title":"EuroIntervention"},{"key":"2025092123022045700_pvaf042-B18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10557-012-6407-z","article-title":"Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction","volume":"26","author":"Alexopoulos","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025092123022045700_pvaf042-B19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B20","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the CANTIC study","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"2025092123022045700_pvaf042-B21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcin.2014.09.007","article-title":"Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early Thieno","volume":"8","author":"Zeymer","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B22","doi-asserted-by":"crossref","first-page":"oead076","DOI":"10.1093\/ehjopen\/oead076","article-title":"Safety of cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study","volume":"3","author":"De Luca","year":"2023","journal-title":"Eur Heart J Open"},{"key":"2025092123022045700_pvaf042-B23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH16-08-0650","article-title":"Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE)","volume":"117","author":"Zeymer","year":"2017","journal-title":"Thromb Haemost"},{"key":"2025092123022045700_pvaf042-B24","doi-asserted-by":"crossref","first-page":"e022125","DOI":"10.1161\/JAHA.121.022125","article-title":"Cangrelor: clinical data, contemporary use, and future perspectives","volume":"10","author":"De Luca","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025092123022045700_pvaf042-B25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1185\/03007995.2014.880050","article-title":"Cangrelor: an emerging therapeutic option for patients with coronary artery disease","volume":"30","author":"Kubica","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2025092123022045700_pvaf042-B26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2025092123022045700_pvaf042-B27","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"2025092123022045700_pvaf042-B28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","article-title":"Switching P2Y12-receptor inhibitors in patients with coronary artery disease","volume":"13","author":"Rollini","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2025092123022045700_pvaf042-B29","first-page":"17","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"key":"2025092123022045700_pvaf042-B30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jcin.2015.02.030","article-title":"Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Franchi","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025092123022045700_pvaf042-B32","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study","volume":"67","author":"Rollini","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025092123022045700_pvaf042-B33","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.116.024872","article-title":"Ticagrelor versus clopidogrel in comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention and hypothermia","volume":"134","author":"Steblovnik","year":"2016","journal-title":"Circulation"},{"key":"2025092123022045700_pvaf042-B34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"key":"2025092123022045700_pvaf042-B35","doi-asserted-by":"crossref","first-page":"ehad655.2148","DOI":"10.1093\/eurheartj\/ehad655.2148","article-title":"P2y12 inhibitor loading time before elective PCI and the prevention of myocardial necrosis","volume":"44","author":"Roule","year":"2023","journal-title":"Eur Heart J"},{"key":"2025092123022045700_pvaf042-B36","first-page":"170","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"66","author":"Byrne","year":"2024","journal-title":"Cor Vasa"},{"key":"2025092123022045700_pvaf042-B37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: emphasis on preserving haemostasis","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2025092123022045700_pvaf042-B38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ehjcvp\/pvu008","article-title":"Risk of thrombocytopenia with glycoprotein IIb\/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials","volume":"1","author":"Wessler","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025092123022045700_pvaf042-B39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00392-006-0459-7","article-title":"Glycoprotein IIb\/IIIa inhibitor-induced thrombocytopenia","volume":"96","author":"Said","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"2025092123022045700_pvaf042-B40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2021.04.013","article-title":"Cangrelor vs. glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention","volume":"238","author":"Yerasi","year":"2021","journal-title":"Am Heart J"},{"key":"2025092123022045700_pvaf042-B41","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/s41598-024-64652-x","article-title":"A dual-center analysis of conservative versus liberal glycoprotein IIb\u2013IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction","volume":"14","author":"Callichurn","year":"2024","journal-title":"Sci Rep"},{"key":"2025092123022045700_pvaf042-B42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ehjcvp\/pvae024","article-title":"Safety and effectiveness of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study","volume":"10","author":"Bruno","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025092123022045700_pvaf042-B43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamacardio.2016.4556","article-title":"Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb\/IIIa inhibitors: an exploratory analysis from the CHAMPION trials","volume":"2","author":"Vaduganathan","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025092123022045700_pvaf042-B44","doi-asserted-by":"crossref","first-page":"e005635","DOI":"10.1161\/CIRCINTERVENTIONS.117.005635","article-title":"Incidence, predictors, and outcomes of acquired thrombocytopenia after percutaneous coronary intervention","volume":"11","author":"Groves","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B45","author":"(EMA) EMA"},{"key":"2025092123022045700_pvaf042-B46","author":"Food and Drug Administration (FDA)"},{"key":"2025092123022045700_pvaf042-B47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/jcm7110442","article-title":"Cangrelor induces more potent platelet inhibition without increasing bleeding in resuscitated patients","volume":"7","author":"Pr\u00fcller","year":"2018","journal-title":"J Clin Med"},{"key":"2025092123022045700_pvaf042-B48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2125.2010.03669.x","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers","volume":"70","author":"Butler","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2025092123022045700_pvaf042-B49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","article-title":"Cangrelor in patients with coronary artery disease pretreated with ticagrelor","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B50","doi-asserted-by":"crossref","first-page":"e024513","DOI":"10.1161\/JAHA.121.024513","article-title":"Cangrelor use patterns and transition to oral P2Y12 inhibitors among patients with myocardial infarction: initial results from the CAMEO registry","volume":"11","author":"Rymer","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025092123022045700_pvaf042-B51","doi-asserted-by":"crossref","first-page":"3197512","DOI":"10.1155\/2023\/3197512","article-title":"Real-world experience with cangrelor as adjuvant to percutaneous coronary intervention: a single-centre observational study","volume":"2023","author":"Thim","year":"2023","journal-title":"Cardiol Res Pract"},{"key":"2025092123022045700_pvaf042-B52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2016.11.017","article-title":"Cangrelor use since FDA approval: a single-center, real-world experience at a tertiary care hospital","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025092123022045700_pvaf042-B53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/joic.12229","article-title":"Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation","volume":"28","author":"Schneider","year":"2015","journal-title":"J Interv Cardiol"},{"key":"2025092123022045700_pvaf042-B54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcin.2016.10.004","article-title":"Randomized comparison of oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor: the ExcelsiorLOAD2 trial","volume":"10","author":"Hochholzer","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B55","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1016\/j.jcin.2023.08.009","article-title":"Switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the switching antiplatelet-6 (SWAP-6) study","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical use of cangrelor: nationwide experience from the Swedish coronary angiography and angioplasty registry (SCAAR)","volume":"5","author":"Grimfj\u00e4rd","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025092123022045700_pvaf042-B57","first-page":"101202","article-title":"Risk of bleeding among cangrelor-treated patients administered upstream P2Y12 inhibitor therapy: the CAMEO registry","volume":"3","author":"Rymer","year":"2024","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"2025092123022045700_pvaf042-B58","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jcin.2017.04.027","article-title":"In vitro pharmacodynamic effects of cangrelor on platelet P2Y12 receptor\u2013mediated signaling in ticagrelor-treated patients","volume":"10","author":"Rollini","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2013.11.019","article-title":"Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor\u2013mediated signaling in prasugrel-treated patients","volume":"7","author":"Rollini","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B60","first-page":"195","article-title":"Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects","volume":"17","author":"Bouman","year":"2009","journal-title":"Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found"},{"key":"2025092123022045700_pvaf042-B61","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"2025092123022045700_pvaf042-B62","first-page":"1303","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"29","author":"Bates","year":"2013","journal-title":"Cardiol Rev"},{"key":"2025092123022045700_pvaf042-B63","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"2025092123022045700_pvaf042-B64","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"2025092123022045700_pvaf042-B65","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1038\/s41598-023-37084-2","article-title":"Comparative effectiveness of cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry","volume":"13","author":"Pepe","year":"2023","journal-title":"Sci Rep"},{"key":"2025092123022045700_pvaf042-B66","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12872-021-02093-4","article-title":"Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch cangrelor registry","volume":"21","author":"Selvarajah","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"2025092123022045700_pvaf042-B67","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/clc.23878","article-title":"Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: study design and interim analysis of the ARCANGELO study","volume":"45","author":"De","year":"2022","journal-title":"Clin Cardiol"},{"key":"2025092123022045700_pvaf042-B68","first-page":"462","article-title":"Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and\/or with cardiogenic shock","volume":"12","author":"Zeymer","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2025092123022045700_pvaf042-B69","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jacc.2023.06.026","article-title":"Long-term outcomes of cardiogenic shock complicating myocardial infarction","volume":"82","author":"Sterling","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025092123022045700_pvaf042-B70","doi-asserted-by":"crossref","first-page":"e006692","DOI":"10.1161\/CIRCOUTCOMES.120.006692","article-title":"Understanding how cardiac arrest complicates the analysis of clinical trials of cardiogenic shock","volume":"13","author":"Jentzer","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025092123022045700_pvaf042-B71","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","article-title":"PCI strategies in patients with acute myocardial infarction and cardiogenic shock","volume":"377","author":"Thiele","year":"2017","journal-title":"N Engl J Med"},{"key":"2025092123022045700_pvaf042-B72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ehjcvp\/pvaa009","article-title":"Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) working group on thrombosis, in association with the acute cardiovascular care association (ACCA) and European association of percutaneous cardiovascular interventions (EAPCI)","volume":"7","author":"Gorog","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025092123022045700_pvaf042-B73","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025092123022045700_pvaf042-B74","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.jcin.2017.09.017","article-title":"Cangrelor or Abciximab as first choice in cardiogenic shock","volume":"10","author":"Lozano","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0002-9149(02)02487-6","article-title":"Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation","volume":"90","author":"Antoniucci","year":"2002","journal-title":"Am J Cardiol"},{"key":"2025092123022045700_pvaf042-B76","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/bcp.13053","article-title":"Abciximab as a bridging strategy to overcome morphine\u2013prasugrel interaction in STEMI patients","volume":"82","author":"Siller-Matula","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025092123022045700_pvaf042-B77","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: a global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"key":"2025092123022045700_pvaf042-B78","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jcin.2017.07.009","article-title":"Cangrelor use in cardiogenic shock: a single-center real-world experience","volume":"10","author":"Vaduganathan","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092123022045700_pvaf042-B79","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele","year":"2012","journal-title":"N Engl J Med"},{"key":"2025092123022045700_pvaf042-B80","doi-asserted-by":"crossref","first-page":"e1309","DOI":"10.4244\/EIJ-D-24-00203","article-title":"Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial","volume":"20","author":"Motovska","year":"2024","journal-title":"EuroIntervention"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf042\/63438992\/pvaf042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/6\/540\/63438992\/pvaf042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/6\/540\/63438992\/pvaf042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T03:02:50Z","timestamp":1758510170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/6\/540\/8157091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":80,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf042","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,5]]}}}